SCHEMBL17508408

SCHEMBL17508408

Cn1c(=O)n(CCCO)c(=O)c2c(Cc3ccccc3)c(-c3cccc(OC(F)(F)F)c3)ncc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TRPC5 Q9UL62 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17523187 0.95 TRPC5 (0.91) TRPC5
SCHEMBL17508799 0.89 TRPC5 (0.80) TRPC5
SCHEMBL17506077 0.86 TRPC5 (1.00) TRPC5
SCHEMBL17501682 0.82 TRPC5 (1.00) TRPC5
SCHEMBL17522770 0.81 TRPC5 (0.90) TRPC5
SCHEMBL17523182 0.78 TRPC5 (0.64) TRPC5
SCHEMBL17501697 0.77 TRPC5 (0.80) TRPC5
SCHEMBL17509561 0.77 TRPC5 (0.68) TRPC5
SCHEMBL17508396 0.75 TRPC5 (0.77) TRPC5
SCHEMBL17501673 0.75 TRPC5 (0.87) TRPC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220031706-A1 TRPC ION CHANNEL INHIBITORS FOR USE IN THERAPY UNIVERSITY OF LEEDS (GB) 2022-02-03 US disclosed
EP-3180337-B1 PYRIDO[3,4-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES HYDRA BIOSCIENCES INC (US) 2018-10-10 EP disclosed
EP-3180337-A1 PYRIDO[3,4-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES Hydra Biosciences, Inc. (US) 2017-06-21 EP disclosed
US-9440973-B2 Pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione derivatives HYDRA BIOSCIENCES, INC. (US) 2016-09-13 US disclosed
US-9440973-B2 Pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione derivatives HYDRA BIOSCIENCES, INC. (US) 2016-09-13 US disclosed
US-9440973-B2 Pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione derivatives HYDRA BIOSCIENCES, INC. (US) 2016-09-13 US disclosed
WO-2016023825-A1 PYRIDO[3,4-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES HYDRA BIOSCIENCES, INC. (US) 2016-02-18 WO disclosed
WO-2016023825-A1 PYRIDO[3,4-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES HYDRA BIOSCIENCES, INC. (US) 2016-02-18 WO disclosed
US-20160039815-A1 PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES HYDRA BIOSCIENCES, INC. 2016-02-11 US disclosed
US-20160039815-A1 PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES HYDRA BIOSCIENCES, INC. 2016-02-11 US disclosed
US-20160039815-A1 PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES HYDRA BIOSCIENCES, INC. 2016-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220031706-A1 TRPC ION CHANNEL INHIBITORS FOR USE IN THERAPY TRPC1, TRPC7, TRPC4 TRPC5 6/4885
US-20160039815-A1 PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES TRPC5, P2RX5, HTR5A TRPC5 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.